Clinical Trial Search

Primary: Mean Change From Baseline at the Final Assessment in Aberrant Behavior Checklist Japanese Version (ABC-J) Irritability Subscale Score — -3.2 units on a scale

Primary: Positive Nasopharynx Biopsy Results Detected by NBI System in Those Post-radiotherapy 8th Week NPC Patient — 14; 1; 20; 1 participants

Primary: Number of Patients With an Acceptable Level of Severe Toxicity as Defined at < Grade 3 CTC Toxicity — 20 participants

Primary: Number of Participants With Palliative Response (Pain or Relief of Neurologic Symptoms) From Single Fraction Radiosurgery Delivered With Tomotherapy — 29 Participants

Primary: Number of Responders — 18 Participants

Primary: Incidence of Graft Versus Host Disease (GvHD) — 1 Participants

Primary: Money Earned — 23.2; 25.0; 20.5; 21.9 US Dollars

Primary: Percent Change From Baseline in Total Hip Bone Mineral Density (BMD) at Week 48 — 1.34; 0.05 Percent change — p=0.014

Primary: Mid Facial Mucosal Level at Implant Site — 0.54; 0.47 mm

Primary: Spirometry Forced Expiratory Volume 1 (FEV1) After Flunisolide — 80.4; 78.7; 85.0; 77.0 % of predicted — p=.148

Primary: Mean Change in BCVA by ETDRS Letter Score From Baseline — 10.5; 7.3; 9.2; 10.5 ETDRS BCVA Letters

Primary: Change in Transferrin Saturation (TSAT) From Baseline to End of Treatment — 21.6; 21.0; 31.7; 20.0 % saturation

Primary: Assessment of Erectile Dysfunction — 64; 64; 59.00; 58 units on a scale

Primary: Mean Continuous Glucose Monitoring Glucose (CGMG) Values During Days 2 to 11 — 141.2; 161.5 milligrams/deciliter (mg/dL) — p=<0.0001

Primary: Mean Continuous Glucose Monitoring Glucose (CGMG) Values During Days 2 to 5 — 136.8; 167.4 milligrams/deciliter (mg/dL)